AI-Powered Care Improvement Solution for High-Risk COPD Patients Takes Shape

Sanofi and Regeneron will collaborate with Viz.ai on an AI-powered care improvement solution for patients with high-risk chronic obstructive pulmonary disease (COPD). The partnership aims to evaluate the Viz COPD module, which uses artificial intelligence (AI) and electronic health record (EHR) data to advance the detection and management of high-risk COPD patients. With COPD affecting over 392 million people globally and being the fourth leading cause of death worldwide, this initiative seeks to improve patient outcomes by streamlining AI-enabled EHR workflows and reducing barriers to therapy.

Key Takeaways:

• The Viz COPD module leverages EHR data and AI to identify high-risk COPD patients in line with established clinical guidelines, flagging them for further follow-up and care.
• The collaboration involves Sanofi, Regeneron, and Viz.ai, aiming to investigate the impact of the Viz COPD module on patient outcomes and care coordination for high-risk COPD patients.
• The Viz COPD module will be integrated into Viz.ai's platform, which is used in over 1,700 hospitals and health systems, with over 60,000 healthcare providers on board.
• The partnership seeks to address unmet needs in COPD care, particularly in underprioritized, underfunded, and undertreated regions.
• Viz.ai's AI-powered care acceleration solution, supported by real-world clinical evidence, aims to deliver significant value to patients, providers, and pharmaceutical companies.

Statistics:

• Estimated 392 million people living with COPD globally.
• COPD is the fourth leading cause of death worldwide.
• The disease adds significant strain to healthcare systems, with each case magnifying the economic toll.
• Over 1,700 hospitals and health systems use Viz.ai's platform for disease diagnosis and care coordination.